Profile data is unavailable for this security.
About the company
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
- Revenue in USD (TTM)210.00k
- Net income in USD-10.74m
- Incorporated1982
- Employees4.00
- LocationAnixa Biosciences Inc3150 Almaden Expy Ste 250SAN JOSE 95118United StatesUSA
- Phone+1 (408) 708-9808
- Fax+1 (302) 655-5049
- Websitehttps://www.anixa.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals Inc | 4.53m | -69.05m | 90.75m | 66.00 | -- | -- | -- | 20.04 | -1.91 | -1.91 | 0.1255 | -0.8877 | 0.0466 | -- | -- | 68,621.21 | -71.11 | -59.78 | -90.34 | -72.70 | -- | -- | -1,524.51 | -1,113.72 | -- | -1.68 | 1.64 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Angion Biomedica Corp | 0.00 | -35.19m | 91.88m | 32.00 | -- | 7.58 | -- | -- | -8.81 | -8.81 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -88.05 | -105.91 | -110.32 | -331.69 | -- | -- | -- | -712.81 | -- | -700.88 | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 92.48m | 47.00 | -- | 3.47 | -- | 92.48 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Allovir Inc | 0.00 | -190.42m | 92.67m | 112.00 | -- | 0.6315 | -- | -- | -1.83 | -1.83 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -81.40 | -52.85 | -91.73 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -31.05m | 92.84m | 43.00 | -- | 6.80 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| BioXcel Therapeutics Inc | 1.38m | -179.05m | 92.96m | 74.00 | -- | -- | -- | 67.36 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Aclaris Therapeutics Inc | 31.25m | -88.48m | 93.36m | 91.00 | -- | 0.5909 | -- | 2.99 | -1.27 | -1.27 | 0.4477 | 2.22 | 0.1383 | -- | 79.92 | 343,395.60 | -39.15 | -47.29 | -44.34 | -53.87 | 42.14 | 44.00 | -283.15 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Curis Inc | 10.02m | -47.41m | 95.31m | 48.00 | -- | 4.85 | -- | 9.51 | -9.02 | -9.02 | 1.89 | 3.34 | 0.1077 | -- | 3.47 | 208,812.50 | -50.95 | -37.25 | -58.32 | -41.12 | 97.88 | 96.05 | -473.04 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Clearside Biomedical Inc | 8.23m | -32.49m | 95.66m | 30.00 | -- | -- | -- | 11.63 | -0.5263 | -0.5263 | 0.1331 | -0.2532 | 0.1928 | -- | 96.78 | 274,200.00 | -76.15 | -63.57 | -89.34 | -81.77 | 95.64 | -- | -394.91 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Eton Pharmaceuticals Inc | 31.64m | -936.00k | 96.33m | 30.00 | -- | 6.22 | -- | 3.04 | -0.0389 | -0.0389 | 1.23 | 0.6025 | 1.11 | 14.42 | 12.02 | 1,054,733.00 | -3.30 | -46.22 | -5.49 | -58.20 | 66.56 | 72.16 | -2.96 | -76.86 | 1.60 | -- | 0.258 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Anixa Biosciences Inc | 210.00k | -10.74m | 96.34m | 4.00 | -- | 3.90 | -- | 458.75 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -86.08m | 98.16m | 68.00 | -- | 0.7372 | -- | -- | -2.15 | -2.15 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -56.91 | -- | -62.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 1.34m | 5.53m | 100.89m | 15.00 | 19.61 | 0.6131 | 19.09 | 75.29 | 0.1270 | 0.1270 | 0.033 | 4.06 | 0.007 | -- | -- | 89,333.34 | 2.66 | -- | 3.13 | -- | -- | -- | 379.70 | -- | -- | -- | 0.2385 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Cue Biopharma Inc | 5.49m | -50.73m | 101.18m | 53.00 | -- | 2.65 | -- | 18.43 | -1.11 | -1.11 | 0.12 | 0.7855 | 0.0719 | -- | 6.26 | 103,584.90 | -66.40 | -57.45 | -81.71 | -68.41 | -- | -- | -924.10 | -810.87 | -- | -- | 0.1804 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to Anixa Biosciences Inc's reporting currency: US Dollar USD
11.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.38m | 4.33% |
| UBS Financial Services, Inc.as of 31 Dec 2023 | 578.64k | 1.81% |
| Mission Wealth Management LPas of 31 Mar 2024 | 502.42k | 1.58% |
| Laird Norton Wealth Management LLCas of 31 Dec 2023 | 368.84k | 1.16% |
| Geode Capital Management LLCas of 31 Dec 2023 | 312.47k | 0.98% |
| Long Focus Capital Management LLCas of 31 Dec 2023 | 165.70k | 0.52% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 151.74k | 0.48% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 108.50k | 0.34% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 73.30k | 0.23% |
| Newton Investment Management North America LLCas of 31 Mar 2024 | 55.35k | 0.17% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
